CUREVAC NV (5CV.DE) Stock Price, Forecast & Analysis
Europe - FRA:5CV - NL0015436031 - Common Stock
5CV.DE Key Statistics, Chart & Performance
The current stock price of 5CV.DE is 4.64 EUR. In the past month the price increased by 0.61%. In the past year, price increased by 78.32%.
5CV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 23.11 | 333.88B | ||
| AMG.DE | AMGEN INC | 13.54 | 137.58B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.68 | 129.12B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.1 | 94.35B | ||
| ARGX.BR | ARGENX SE | 66.06 | 43.76B | ||
| 1AE.DE | ARGENX SE | 65.52 | 43.41B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.21B | ||
| IDP.DE | BIOGEN INC | 9.15 | 19.43B | ||
| 1BIIB.MI | BIOGEN INC | 9.53 | 19.37B | ||
| 0QF.DE | MODERNA INC | N/A | 9.23B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.19B | ||
| 1MDGL.MI | N/A | 8.46B |
Related stock screener links
About 5CV.DE
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 825
Phone: 49707198830
CUREVAC NV / 5CV.DE FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Can you provide the latest stock price for CUREVAC NV?
The current stock price of 5CV.DE is 4.64 EUR. The price increased by 0.26% in the last trading session.
Does 5CV stock pay dividends?
5CV.DE does not pay a dividend.
How is the ChartMill rating for CUREVAC NV?
5CV.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of 5CV stock?
CUREVAC NV (5CV.DE) operates in the Health Care sector and the Biotechnology industry.
What is CUREVAC NV worth?
CUREVAC NV (5CV.DE) has a market capitalization of 1.04B EUR. This makes 5CV.DE a Small Cap stock.
Can you provide the upcoming earnings date for CUREVAC NV?
CUREVAC NV (5CV.DE) will report earnings on 2025-11-18.
5CV.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is one of the better performing stocks in the market, outperforming 92.87% of all stocks.
5CV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE. 5CV.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
5CV.DE Financial Highlights
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS increased by 170.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.93% | ||
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| Debt/Equity | 0.05 |
5CV.DE Forecast & Estimates
13 analysts have analysed 5CV.DE and the average price target is 4.2 EUR. This implies a price decrease of -9.39% is expected in the next year compared to the current price of 4.64.
For the next year, analysts expect an EPS growth of -170.56% and a revenue growth -86.75% for 5CV.DE